547
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study

, , , , , , , , , , & show all
Pages 1110-1117 | Accepted 11 Jun 2012, Published online: 06 Jul 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Daniela Paola Roggeri, Mario Cozzolino, Sandro Mazzaferro, Diego Brancaccio, Ernesto Paoletti, Alessandro Roggeri, Anna Maria Costanzo, Umberto di Luzio Paparatti, Vincenzo Festa & Piergiorgio Messa. (2015) Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study. International Journal of Nephrology and Renovascular Disease 8, pages 1-6.
Read now
Farhanah Yousaf & Chaim Charytan. (2014) Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. Renal Failure 36:1, pages 131-138.
Read now

Articles from other publishers (4)

Caroline Freeman, Lucia Giles, Polly Field, Elisabeth Sörstadius & Heleen van Haalen. (2019) Humanistic burden and economic impact of chronic kidney disease: a systematic literature review. F1000Research 8, pages 2142.
Crossref
Paul Landais, Sihame Chkair, Thierry Chevallier, Mariella Lomma, Yannick Le Manach & Jean-Pierre Daurès. (2016) Health-Economic Researches in Perioperative Medicine. Current Anesthesiology Reports 6:3, pages 299-304.
Crossref
Mark Nuijten, Daniela P. Roggeri, Alessandro Roggeri, Paolo Novelli & Thomas S. Marshall. (2015) Health Economic Evaluation of Paricalcitol® Versus Cincalcet + Calcitriol (Oral) in Italy. Clinical Drug Investigation 35:4, pages 229-238.
Crossref
Andrea Galassi, Antonio Bellasi, Sara Auricchio, Sergio Papagni & Mario Cozzolino. (2013) Which Vitamin D in CKD-MBD? The Time of Burning Questions. BioMed Research International 2013, pages 1-10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.